市場調査レポート
商品コード
1459488

ジェネリック医薬品の世界市場 2024-2028

Global Generic drugs Market 2024-2028

出版日: | 発行: TechNavio | ページ情報: 英文 168 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.74円
ジェネリック医薬品の世界市場 2024-2028
出版日: 2024年03月19日
発行: TechNavio
ページ情報: 英文 168 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ジェネリック医薬品市場は2023-2028年に2,125億8,000万米ドル、予測期間中のCAGRは7.86%で成長すると予測されています。

当レポートでは、ジェネリック医薬品市場の全体的な分析、市場規模・予測、動向、成長促進要因、課題、約25のベンダーを網羅したベンダー分析などを掲載しています。

現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。市場を牽引しているのは、ブランド医薬品に代わる低コストの医薬品、創薬・市場開拓のアウトソーシングの増加、ブランド医薬品の特許切れ増加などです。

市場範囲
基準年 2024
終了年 2028
予測期間 2024-2028
成長モメンタム 加速
前年比2024年 6.62%
CAGR 7.86%
増分額 2,125億8,000万米ドル

本調査では、RPA(ロボティック・プロセス・オートメーション)の登場が今後数年間のジェネリック医薬品市場成長を牽引する主要因の1つであると分析しています。また、市場ベンダー間のM&Aの上昇と病院所有のジェネリック医薬品の出現は、市場の大規模な需要につながります。

目次

第1章 エグゼクティブサマリー

  • 市場概要

第2章 市場情勢

  • 市場エコシステム

第3章 市場規模の評価

  • 市場の定義
  • 市場セグメント分析
  • 市場規模 2023
  • 市場の見通し 2023-2028

第4章 市場規模実績

  • ジェネリック医薬品の世界市場 2018-2022
  • 投与経路セグメント分析 2018-2022
  • タイプセグメント分析 2018-2022
  • 地域別セグメント分析 2018-2022
  • 国別セグメント分析 2018-2022

第5章 ファイブフォース分析

  • ファイブフォースの要約
  • 買い手の交渉力
  • 供給企業の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争の脅威
  • 市況

第6章 市場セグメンテーション:投与経路別

  • 市場セグメント
  • 比較:投与経路別
  • 経口:市場規模と予測 2023-2028
  • 注射剤:市場規模と予測 2023-2028
  • 外用薬:市場規模と予測 2023-2028
  • 吸入器:市場規模と予測 2023-2028
  • 市場機会:投与経路別

第7章 市場セグメンテーション:タイプ別

  • 市場セグメント
  • 比較:タイプ別
  • 低分子ジェネリック:市場規模と予測 2023-2028
  • バイオシミラー:市場規模と予測 2023-2028
  • 市場機会:タイプ別

第8章 顧客情勢

  • 顧客情勢の概要

第9章 地域別情勢

  • 地域別セグメンテーション
  • 地域別比較
  • 北米:市場規模と予測 2023-2028
  • 欧州:市場規模と予測 2023-2028
  • アジア:市場規模と予測 2023-2028
  • 世界のその他の地域:市場規模と予測 2023-2028
  • 米国:市場規模と予測 2023-2028
  • ドイツ:市場規模と予測 2023-2028
  • 中国:市場規模と予測 2023-2028
  • 英国:市場規模と予測 2023-2028
  • インド:市場規模と予測 2023-2028
  • 市場機会:地域情勢別

第10章 促進要因、課題、および動向

  • 市場促進要因
  • 市場の課題
  • 促進要因と課題の影響
  • 市場動向

第11章 ベンダー情勢

  • 概要
  • ベンダー情勢
  • 混乱の状況
  • 業界のリスク

第12章 ベンダー分析

  • 対象ベンダー
  • ベンダーの市場ポジショニング
  • Amgen Inc.
  • Aurobindo Pharma Ltd.
  • Baxter International Inc.
  • Biocon Ltd.
  • Cadila Pharmaceuticals Ltd.
  • Cipla Ltd.
  • Dr Reddys Laboratories Ltd.
  • Fresenius SE and Co. KGaA
  • Merck and Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

第13章 付録

図表

Exhibits:

  • Exhibits1: Executive Summary - Chart on Market Overview
  • Exhibits2: Executive Summary - Data Table on Market Overview
  • Exhibits3: Executive Summary - Chart on Global Market Characteristics
  • Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
  • Exhibits5: Executive Summary - Chart on Market Segmentation by Route of Administration
  • Exhibits6: Executive Summary - Chart on Market Segmentation by Type
  • Exhibits7: Executive Summary - Chart on Incremental Growth
  • Exhibits8: Executive Summary - Data Table on Incremental Growth
  • Exhibits9: Executive Summary - Chart on Vendor Market Positioning
  • Exhibits10: Parent market
  • Exhibits11: Market Characteristics
  • Exhibits12: Offerings of vendors included in the market definition
  • Exhibits13: Market segments
  • Exhibits14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
  • Exhibits15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
  • Exhibits16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
  • Exhibits17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
  • Exhibits18: Historic Market Size - Data Table on global generic drugs market 2018 - 2022 ($ billion)
  • Exhibits19: Historic Market Size - Route of administration Segment 2018 - 2022 ($ billion)
  • Exhibits20: Historic Market Size - Type Segment 2018 - 2022 ($ billion)
  • Exhibits21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
  • Exhibits22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)
  • Exhibits23: Five forces analysis - Comparison between 2023 and 2028
  • Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
  • Exhibits25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
  • Exhibits26: Threat of new entrants - Impact of key factors in 2023 and 2028
  • Exhibits27: Threat of substitutes - Impact of key factors in 2023 and 2028
  • Exhibits28: Threat of rivalry - Impact of key factors in 2023 and 2028
  • Exhibits29: Chart on Market condition - Five forces 2023 and 2028
  • Exhibits30: Chart on Route of Administration - Market share 2023-2028 (%)
  • Exhibits31: Data Table on Route of Administration - Market share 2023-2028 (%)
  • Exhibits32: Chart on Comparison by Route of Administration
  • Exhibits33: Data Table on Comparison by Route of Administration
  • Exhibits34: Chart on Oral - Market size and forecast 2023-2028 ($ billion)
  • Exhibits35: Data Table on Oral - Market size and forecast 2023-2028 ($ billion)
  • Exhibits36: Chart on Oral - Year-over-year growth 2023-2028 (%)
  • Exhibits37: Data Table on Oral - Year-over-year growth 2023-2028 (%)
  • Exhibits38: Chart on Injectables - Market size and forecast 2023-2028 ($ billion)
  • Exhibits39: Data Table on Injectables - Market size and forecast 2023-2028 ($ billion)
  • Exhibits40: Chart on Injectables - Year-over-year growth 2023-2028 (%)
  • Exhibits41: Data Table on Injectables - Year-over-year growth 2023-2028 (%)
  • Exhibits42: Chart on Topical - Market size and forecast 2023-2028 ($ billion)
  • Exhibits43: Data Table on Topical - Market size and forecast 2023-2028 ($ billion)
  • Exhibits44: Chart on Topical - Year-over-year growth 2023-2028 (%)
  • Exhibits45: Data Table on Topical - Year-over-year growth 2023-2028 (%)
  • Exhibits46: Chart on Inhalers - Market size and forecast 2023-2028 ($ billion)
  • Exhibits47: Data Table on Inhalers - Market size and forecast 2023-2028 ($ billion)
  • Exhibits48: Chart on Inhalers - Year-over-year growth 2023-2028 (%)
  • Exhibits49: Data Table on Inhalers - Year-over-year growth 2023-2028 (%)
  • Exhibits50: Market opportunity by Route of Administration ($ billion)
  • Exhibits51: Data Table on Market opportunity by Route of Administration ($ billion)
  • Exhibits52: Chart on Type - Market share 2023-2028 (%)
  • Exhibits53: Data Table on Type - Market share 2023-2028 (%)
  • Exhibits54: Chart on Comparison by Type
  • Exhibits55: Data Table on Comparison by Type
  • Exhibits56: Chart on Small-molecule generics - Market size and forecast 2023-2028 ($ billion)
  • Exhibits57: Data Table on Small-molecule generics - Market size and forecast 2023-2028 ($ billion)
  • Exhibits58: Chart on Small-molecule generics - Year-over-year growth 2023-2028 (%)
  • Exhibits59: Data Table on Small-molecule generics - Year-over-year growth 2023-2028 (%)
  • Exhibits60: Chart on Biosimilars - Market size and forecast 2023-2028 ($ billion)
  • Exhibits61: Data Table on Biosimilars - Market size and forecast 2023-2028 ($ billion)
  • Exhibits62: Chart on Biosimilars - Year-over-year growth 2023-2028 (%)
  • Exhibits63: Data Table on Biosimilars - Year-over-year growth 2023-2028 (%)
  • Exhibits64: Market opportunity by Type ($ billion)
  • Exhibits65: Data Table on Market opportunity by Type ($ billion)
  • Exhibits66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Exhibits67: Chart on Market share By Geographical Landscape 2023-2028 (%)
  • Exhibits68: Data Table on Market share By Geographical Landscape 2023-2028 (%)
  • Exhibits69: Chart on Geographic comparison
  • Exhibits70: Data Table on Geographic comparison
  • Exhibits71: Chart on North America - Market size and forecast 2023-2028 ($ billion)
  • Exhibits72: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
  • Exhibits73: Chart on North America - Year-over-year growth 2023-2028 (%)
  • Exhibits74: Data Table on North America - Year-over-year growth 2023-2028 (%)
  • Exhibits75: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
  • Exhibits76: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
  • Exhibits77: Chart on Europe - Year-over-year growth 2023-2028 (%)
  • Exhibits78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
  • Exhibits79: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
  • Exhibits80: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
  • Exhibits81: Chart on Asia - Year-over-year growth 2023-2028 (%)
  • Exhibits82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
  • Exhibits83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
  • Exhibits84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
  • Exhibits85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
  • Exhibits86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
  • Exhibits87: Chart on US - Market size and forecast 2023-2028 ($ billion)
  • Exhibits88: Data Table on US - Market size and forecast 2023-2028 ($ billion)
  • Exhibits89: Chart on US - Year-over-year growth 2023-2028 (%)
  • Exhibits90: Data Table on US - Year-over-year growth 2023-2028 (%)
  • Exhibits91: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
  • Exhibits92: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
  • Exhibits93: Chart on Germany - Year-over-year growth 2023-2028 (%)
  • Exhibits94: Data Table on Germany - Year-over-year growth 2023-2028 (%)
  • Exhibits95: Chart on China - Market size and forecast 2023-2028 ($ billion)
  • Exhibits96: Data Table on China - Market size and forecast 2023-2028 ($ billion)
  • Exhibits97: Chart on China - Year-over-year growth 2023-2028 (%)
  • Exhibits98: Data Table on China - Year-over-year growth 2023-2028 (%)
  • Exhibits99: Chart on UK - Market size and forecast 2023-2028 ($ billion)
  • Exhibits100: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
  • Exhibits101: Chart on UK - Year-over-year growth 2023-2028 (%)
  • Exhibits102: Data Table on UK - Year-over-year growth 2023-2028 (%)
  • Exhibits103: Chart on India - Market size and forecast 2023-2028 ($ billion)
  • Exhibits104: Data Table on India - Market size and forecast 2023-2028 ($ billion)
  • Exhibits105: Chart on India - Year-over-year growth 2023-2028 (%)
  • Exhibits106: Data Table on India - Year-over-year growth 2023-2028 (%)
  • Exhibits107: Market opportunity By Geographical Landscape ($ billion)
  • Exhibits108: Data Tables on Market opportunity By Geographical Landscape ($ billion)
  • Exhibits109: Impact of drivers and challenges in 2023 and 2028
  • Exhibits110: Overview on Criticality of inputs and Factors of differentiation
  • Exhibits111: Overview on factors of disruption
  • Exhibits112: Impact of key risks on business
  • Exhibits113: Vendors covered
  • Exhibits114: Matrix on vendor position and classification
  • Exhibits115: Amgen Inc. - Overview
  • Exhibits116: Amgen Inc. - Product / Service
  • Exhibits117: Amgen Inc. - Key offerings
  • Exhibits118: Aurobindo Pharma Ltd. - Overview
  • Exhibits119: Aurobindo Pharma Ltd. - Product / Service
  • Exhibits120: Aurobindo Pharma Ltd. - Key offerings
  • Exhibits121: Baxter International Inc. - Overview
  • Exhibits122: Baxter International Inc. - Business segments
  • Exhibits123: Baxter International Inc. - Key news
  • Exhibits124: Baxter International Inc. - Key offerings
  • Exhibits125: Baxter International Inc. - Segment focus
  • Exhibits126: Biocon Ltd. - Overview
  • Exhibits127: Biocon Ltd. - Business segments
  • Exhibits128: Biocon Ltd. - Key news
  • Exhibits129: Biocon Ltd. - Key offerings
  • Exhibits130: Biocon Ltd. - Segment focus
  • Exhibits131: Cadila Pharmaceuticals Ltd. - Overview
  • Exhibits132: Cadila Pharmaceuticals Ltd. - Product / Service
  • Exhibits133: Cadila Pharmaceuticals Ltd. - Key offerings
  • Exhibits134: Cipla Ltd. - Overview
  • Exhibits135: Cipla Ltd. - Business segments
  • Exhibits136: Cipla Ltd. - Key news
  • Exhibits137: Cipla Ltd. - Key offerings
  • Exhibits138: Cipla Ltd. - Segment focus
  • Exhibits139: Dr Reddys Laboratories Ltd. - Overview
  • Exhibits140: Dr Reddys Laboratories Ltd. - Business segments
  • Exhibits141: Dr Reddys Laboratories Ltd. - Key offerings
  • Exhibits142: Dr Reddys Laboratories Ltd. - Segment focus
  • Exhibits143: Fresenius SE and Co. KGaA - Overview
  • Exhibits144: Fresenius SE and Co. KGaA - Business segments
  • Exhibits145: Fresenius SE and Co. KGaA - Key news
  • Exhibits146: Fresenius SE and Co. KGaA - Key offerings
  • Exhibits147: Fresenius SE and Co. KGaA - Segment focus
  • Exhibits148: Merck and Co. Inc. - Overview
  • Exhibits149: Merck and Co. Inc. - Business segments
  • Exhibits150: Merck and Co. Inc. - Key news
  • Exhibits151: Merck and Co. Inc. - Key offerings
  • Exhibits152: Merck and Co. Inc. - Segment focus
  • Exhibits153: Novartis AG - Overview
  • Exhibits154: Novartis AG - Business segments
  • Exhibits155: Novartis AG - Key news
  • Exhibits156: Novartis AG - Key offerings
  • Exhibits157: Novartis AG - Segment focus
  • Exhibits158: Pfizer Inc. - Overview
  • Exhibits159: Pfizer Inc. - Product / Service
  • Exhibits160: Pfizer Inc. - Key news
  • Exhibits161: Pfizer Inc. - Key offerings
  • Exhibits162: Sanofi SA - Overview
  • Exhibits163: Sanofi SA - Business segments
  • Exhibits164: Sanofi SA - Key news
  • Exhibits165: Sanofi SA - Key offerings
  • Exhibits166: Sanofi SA - Segment focus
  • Exhibits167: Sun Pharmaceutical Industries Ltd. - Overview
  • Exhibits168: Sun Pharmaceutical Industries Ltd. - Product / Service
  • Exhibits169: Sun Pharmaceutical Industries Ltd. - Key news
  • Exhibits170: Sun Pharmaceutical Industries Ltd. - Key offerings
  • Exhibits171: Teva Pharmaceutical Industries Ltd. - Overview
  • Exhibits172: Teva Pharmaceutical Industries Ltd. - Business segments
  • Exhibits173: Teva Pharmaceutical Industries Ltd. - Key news
  • Exhibits174: Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibits175: Teva Pharmaceutical Industries Ltd. - Segment focus
  • Exhibits176: Viatris Inc. - Overview
  • Exhibits177: Viatris Inc. - Business segments
  • Exhibits178: Viatris Inc. - Key news
  • Exhibits179: Viatris Inc. - Key offerings
  • Exhibits180: Viatris Inc. - Segment focus
  • Exhibits181: Inclusions checklist
  • Exhibits182: Exclusions checklist
  • Exhibits183: Currency conversion rates for US$
  • Exhibits184: Research methodology
  • Exhibits185: Validation techniques employed for market sizing
  • Exhibits186: Information sources
  • Exhibits187: List of abbreviations
目次
Product Code: IRTNTR44584

The generic drugs market is forecasted to grow by USD 212.58 bn during 2023-2028, accelerating at a CAGR of 7.86% during the forecast period. The report on the generic drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by low-cost alternatives to branded medicines, increased outsourcing of drug discovery and development, and rising expiry of patents on branded drugs.

Technavio's generic drugs market is segmented as below:

Market Scope
Base Year2024
End Year2028
Series Year2024-2028
Growth MomentumAccelerate
YOY 20246.62%
CAGR7.86%
Incremental Value$212.58bn

By Route Of Administration

  • Oral
  • Injectables
  • Topical
  • Inhalers

By Type

  • Small-molecule generics
  • Biosimilars

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)

This study identifies the advent of RPA (robotic process automation) as one of the prime reasons driving the generic drugs market growth during the next few years. Also, rising m and a among market vendors and the emergence of hospital-owned generics will lead to sizable demand in the market.

The report on the generic drugs market covers the following areas:

  • Generic drugs market sizing
  • Generic drugs market forecast
  • Generic drugs market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading generic drugs market vendors that include Abbott Laboratories, Amgen Inc., Amneal Pharmaceuticals Inc., Apotex Inc., Aspen Pharmacare Holdings Ltd, Aurobindo Pharma Ltd., Baxter International Inc., Biocon Ltd., Cadila Pharmaceuticals Ltd., Cipla Ltd., Dr Reddys Laboratories Ltd., Eli Lilly and Co., Endo International Plc, Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, Hikma Pharmaceuticals Plc, Lupin Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., PlantForm Corporation, Sanofi SA, STADA Arzneimittel AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc. Also, the generic drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources through an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

  • 1.1 Market overview

2 Market Landscape

  • 2.1 Market ecosystem

3 Market Sizing

  • 3.1 Market definition
  • 3.2 Market segment analysis
  • 3.3 Market size 2023
  • 3.4 Market outlook: Forecast for 2023-2028

4 Historic Market Size

  • 4.1 Global generic drugs market 2018 - 2022
  • 4.2 Route of administration Segment Analysis 2018 - 2022
  • 4.3 Type Segment Analysis 2018 - 2022
  • 4.4 Geography Segment Analysis 2018 - 2022
  • 4.5 Country Segment Analysis 2018 - 2022

5 Five Forces Analysis

  • 5.1 Five forces summary
  • 5.2 Bargaining power of buyers
  • 5.3 Bargaining power of suppliers
  • 5.4 Threat of new entrants
  • 5.5 Threat of substitutes
  • 5.6 Threat of rivalry
  • 5.7 Market condition

6 Market Segmentation by Route of Administration

  • 6.1 Market segments
  • 6.2 Comparison by Route of Administration
  • 6.3 Oral - Market size and forecast 2023-2028
  • 6.4 Injectables - Market size and forecast 2023-2028
  • 6.5 Topical - Market size and forecast 2023-2028
  • 6.6 Inhalers - Market size and forecast 2023-2028
  • 6.7 Market opportunity by Route of Administration

7 Market Segmentation by Type

  • 7.1 Market segments
  • 7.2 Comparison by Type
  • 7.3 Small-molecule generics - Market size and forecast 2023-2028
  • 7.4 Biosimilars - Market size and forecast 2023-2028
  • 7.5 Market opportunity by Type

8 Customer Landscape

  • 8.1 Customer landscape overview

9 Geographic Landscape

  • 9.1 Geographic segmentation
  • 9.2 Geographic comparison
  • 9.3 North America - Market size and forecast 2023-2028
  • 9.4 Europe - Market size and forecast 2023-2028
  • 9.5 Asia - Market size and forecast 2023-2028
  • 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
  • 9.7 US - Market size and forecast 2023-2028
  • 9.8 Germany - Market size and forecast 2023-2028
  • 9.9 China - Market size and forecast 2023-2028
  • 9.10 UK - Market size and forecast 2023-2028
  • 9.11 India - Market size and forecast 2023-2028
  • 9.12 Market opportunity By Geographical Landscape

10 Drivers, Challenges, and Trends

  • 10.1 Market drivers
  • 10.2 Market challenges
  • 10.3 Impact of drivers and challenges
  • 10.4 Market trends

11 Vendor Landscape

  • 11.1 Overview
  • 11.2 Vendor landscape
  • 11.3 Landscape disruption
  • 11.4 Industry risks

12 Vendor Analysis

  • 12.1 Vendors covered
  • 12.2 Market positioning of vendors
  • 12.3 Amgen Inc.
  • 12.4 Aurobindo Pharma Ltd.
  • 12.5 Baxter International Inc.
  • 12.6 Biocon Ltd.
  • 12.7 Cadila Pharmaceuticals Ltd.
  • 12.8 Cipla Ltd.
  • 12.9 Dr Reddys Laboratories Ltd.
  • 12.10 Fresenius SE and Co. KGaA
  • 12.11 Merck and Co. Inc.
  • 12.12 Novartis AG
  • 12.13 Pfizer Inc.
  • 12.14 Sanofi SA
  • 12.15 Sun Pharmaceutical Industries Ltd.
  • 12.16 Teva Pharmaceutical Industries Ltd.
  • 12.17 Viatris Inc.

13 Appendix

  • 13.1 Scope of the report
  • 13.2 Inclusions and exclusions checklist
  • 13.3 Currency conversion rates for US$
  • 13.4 Research methodology
  • 13.5 List of abbreviations